about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuIntegrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityNovel technologies and emerging biomarkers for personalized cancer immunotherapySystems Biology Approach for Cancer Vaccine Development and EvaluationWhole Tumor Antigen Vaccines: Where Are We?Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerTranslational implications of tumor heterogeneityAcquired and intrinsic resistance in cancer immunotherapyBeyond model antigens: high-dimensional methods for the analysis of antigen-specific T cellsOncolytic viruses as anticancer vaccinesOpportunities for immunotherapy in microsatellite instable colorectal cancerT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesTumor neoantigens: building a framework for personalized cancer immunotherapyPOLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial CancerNeo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumorsINTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discoverySystematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Identification of trunk mutations in gastric carcinoma: a case studyHigh sensitivity of cancer exome-based CD8 T cell neo-antigen identificationA novel minigene scaffold for therapeutic cancer vaccinesNeoantigens in cancer immunotherapy.SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutationWhole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanomaCharacterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Mutational profiling of colorectal cancers with microsatellite instability.Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomesRecent advances and future of immunotherapy for glioblastoma.Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases.Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides.TCR repertoires of intratumoral T-cell subsets.
P2860
Q21131200-C5FB9FE2-F1D2-45CA-8A5F-B7F6B8B298B6Q26769744-08FC812B-7FEE-497B-B0D8-705D73D197DEQ26770780-D274C6A2-2986-4573-A723-F8517D2086B0Q26782580-9015BE28-E518-464B-A260-3B5A27B66595Q26783866-AF85E2DD-027B-41CB-9F9D-AD7416D45C85Q26798074-4844366B-DFC2-4F88-95B1-B84C6289FD9EQ26822823-C13F4F46-657C-4F7F-A901-E85E2A030F9CQ26827701-E6D400B0-BDA2-4478-BD30-4DE5B78E36C6Q27013972-847BA2FC-3E26-4864-B705-E3F2D3CB5C10Q27025600-9D312DD8-9661-4893-B840-412809BD0CD3Q28066110-7C17CE51-7F2D-4BEE-8C1F-E45A47DFD9ACQ28074619-68AEA359-8C35-4CD7-ACAC-C2C10AA49D09Q28082704-17D2503B-36D1-48E4-A0C2-485AF8230731Q28260529-9A9A12EF-0E42-4B8E-818D-D57C56BD0EF0Q33564510-BB8DAACE-29A2-418D-B67B-A62E99940DE0Q33606161-2863F47D-0315-4E60-BB49-C5B47D77FFD0Q33613761-7600CA1D-9C6E-48E1-AEFA-F1385DFC7BA1Q33917224-88F57AEC-5B42-429C-8EDF-3A8BA41E6638Q33921459-35A5A903-4F19-4E80-BE9B-E44D5D110EE2Q33930588-0C4C8935-98BC-42F9-A683-6792C6369F58Q34418540-5C59399E-F3F8-4C42-9E13-6F98BAA8430AQ34470074-9458A61B-E30A-4521-8011-9CC671144F5FQ34558043-857C50DC-02CE-408A-BE0B-183D67191AD4Q34559389-C71A38A9-9FFE-417D-BD28-913FFD1C5E38Q34619293-8F69FAD3-291E-47CC-8FE2-7F9B43093F10Q35040888-F08A9367-B962-45A1-BAA0-BC319CB4FE43Q35176032-50617091-CE7B-413B-9749-EF447D4C5675Q35227810-1B1764EE-34E6-4A02-A000-B2AD74A09E43Q36021163-1C7F14B0-6C09-4A36-A939-86038E60E287Q36024656-B5402260-2482-4E6F-981F-6B8F33C441ADQ36050577-1D571134-52B3-43FD-9644-5628C2628761Q36165605-36DF8851-613B-48EC-976E-6E7833083206Q36316627-8292007C-624F-40C2-9B9B-3E119D18B433Q36561768-04A25F02-88B3-4DEF-AF96-70AD265F7F30Q36860418-19DBE2A4-D051-4023-AB57-A21F2E9C7264Q37096363-49B8996A-3983-4BEA-8DDD-F1988D796BF4Q37239071-4530786F-844F-4C2B-920D-648090B08ECAQ37477282-38DEB685-07E6-4A98-A286-D60775FC27BAQ37718264-639F2AB4-5121-4D6B-A0A9-0A835473448AQ38170497-FE28C5EA-AE2A-46CC-BF5E-23508A44347F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The cancer antigenome.
@en
type
label
The cancer antigenome.
@en
prefLabel
The cancer antigenome.
@en
P2093
P2860
P356
P1433
P1476
The cancer antigenome.
@en
P2093
Bianca Heemskerk
Pia Kvistborg
Ton N M Schumacher
P2860
P304
P356
10.1038/EMBOJ.2012.333
P407
P577
2012-12-21T00:00:00Z